Characteristics of patients with WM
| Variables . | Number of patients . |
|---|---|
| Number of patients (male/female, n) | 106 (46/60) |
| Age in years, median (IQR) | 73 (64-81) |
| Symptomatic WM Asymptomatic WM | n = 78 (73.5%) n = 28 (26.5) |
| Vaccination with BNT162b2 | n = 90 (67 symptomatic and 23 asymptomatic) (84.9%) |
| Vaccination with AZD1222 | n = 16 (11 symptomatic and 5 asymptomatic) (15.1%) |
| Patients on active treatment at the time of vaccination Type of therapy | n = 33/78 (42.3%) Rituximab-ibrutinib: n = 16 BTKi monotherapy (ibrutinib, acalabrutinib, zanubrutinib): n = 16 Rituximab: n = 1 |
| Comorbidities | Pulmonary disease: n = 7 (6.6%) Diabetes mellitus: n = 9 (8.5%) Autoimmune disease: n = 4 (3.8%) Cardiovascular disease: n = 48 (45.3%) |
| Immunoglobulins, median ± SD, mg/dL | IgG: 762.6 ± 627 IgA: 96 ± 83.7 IgM: 1338 ± 1436 |
| Total lymphocyte count, median ± SD, cells/mm3 | 2030 ± 1206 |
| Variables . | Number of patients . |
|---|---|
| Number of patients (male/female, n) | 106 (46/60) |
| Age in years, median (IQR) | 73 (64-81) |
| Symptomatic WM Asymptomatic WM | n = 78 (73.5%) n = 28 (26.5) |
| Vaccination with BNT162b2 | n = 90 (67 symptomatic and 23 asymptomatic) (84.9%) |
| Vaccination with AZD1222 | n = 16 (11 symptomatic and 5 asymptomatic) (15.1%) |
| Patients on active treatment at the time of vaccination Type of therapy | n = 33/78 (42.3%) Rituximab-ibrutinib: n = 16 BTKi monotherapy (ibrutinib, acalabrutinib, zanubrutinib): n = 16 Rituximab: n = 1 |
| Comorbidities | Pulmonary disease: n = 7 (6.6%) Diabetes mellitus: n = 9 (8.5%) Autoimmune disease: n = 4 (3.8%) Cardiovascular disease: n = 48 (45.3%) |
| Immunoglobulins, median ± SD, mg/dL | IgG: 762.6 ± 627 IgA: 96 ± 83.7 IgM: 1338 ± 1436 |
| Total lymphocyte count, median ± SD, cells/mm3 | 2030 ± 1206 |